Graham Britton

Dr. Graham Britton

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Immunity
Verified
Journal Article
Closed access
NVNicolas Vabret
Nicolas Vabret
GBGraham Britton
Graham Britton
CGConor Gruber
Conor Gruber
SHSamarth Hegde
Samarth Hegde
JKJoel Kim
Joel Kim
ULUri Laserson
Uri Laserson

1 January 2019 in Immunity
Verified
Journal Article
Closed access
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
IMIlaria Mogno
Ilaria Mogno
OVOlivia H. Vennaro
Olivia H. Vennaro
SLSean R. Llewellyn
Sean R. Llewellyn
JFJeremiah J. Faith
Jeremiah J. Faith

1 March 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SLSean R. Llewellyn
Sean R. Llewellyn
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
OVOlivia H. Vennaro
Olivia H. Vennaro
AMArthur Mortha
Arthur Mortha
JFJeremiah J. Faith
Jeremiah J. Faith

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TNT. H. Sky Ng
T. H. Sky Ng
GBGraham Britton
Graham Britton
EHElaine V. Hill
Elaine V. Hill
JVJohan Verhagen
Johan Verhagen
BBBronwen R. Burton
Bronwen R. Burton
DWDavid C. Wraith
David C. Wraith
Since the discovery of interleukin-10 (IL-10) in the 1980s, a large body of work has led to its recognition as a pleiotropic immunomodulatory cytokine that affects both the innate and adaptive immune systems. IL-10 is produced by a wide range of cell types, but for the purposes of this review we shall focus on IL-10 secreted by CD4+ T cells. Here we describe the importance of IL-10 as a mediator of suppression used by both FoxP3+ and FoxP3− T regulatory cells. Moreover, we discuss the molecular events leading to the induction of IL-10 secretion in T helper cell subsets, where it acts as a pivotal negative feedback mechanism. Finally we discuss how a greater understanding of this principle has allowed for the design of more efficient, antigen-specific immunotherapy strategies to exploit this natural phenomenon clinically.

29 April 2019 in Gut
Verified
Journal Article
Closed access
PDF file
JTJoana Torres
Joana Torres
JHJianzhong Hu
Jianzhong Hu
ASAkihiro Seki
Akihiro Seki
CECaroline Eisele
Caroline Eisele
NNNilendra Nair
Nilendra Nair
IPInga Peter
Inga Peter
Background and aims: Prenatal and early life bacterial colonisation is thought to play a major role in shaping the immune system. Furthermore, accumulating evidence links early life exposures to the risk of developing IBD later in life. We aimed to assess the effect of maternal IBD on the composition of the microbiome during pregnancy and on the offspring’s microbiome. Methods: We prospectively examined the diversity and taxonomy of the microbiome of pregnant women with and without IBD and their babies at multiple time points. We evaluated the role of maternal IBD diagnosis, the mode of delivery, antibiotic use and feeding behaviour on the microbiome composition during early life. To assess the effects of IBD-associated maternal and infant microbiota on the enteric immune system, we inoculated germ-free mice (GFM) with the respective stool and profiled adaptive and innate immune cell populations in the murine intestines. Results: Pregnant women with IBD and their offspring presented with lower bacterial diversity and altered bacterial composition compared with control women and their babies. Maternal IBD was the main predictor of the microbiota diversity in the infant gut at 7, 14, 30, 60 and 90 days of life. Babies born to mothers with IBD demonstrated enrichment in Gammaproteobacteria and depletion in Bifidobacteria. Finally, GFM inoculated with third trimester IBD mother and 90-day infant stools showed significantly reduced microbial diversity and fewer class-switched memory B cells and regulatory T cells in the colon. Conclusion: Aberrant gut microbiota composition persists during pregnancy with IBD and alters the bacterial diversity and abundance in the infant stool. The dysbiotic microbiota triggered abnormal imprinting of the intestinal immune system in GFM.

22 January 2019 in eLife
Verified
Journal Article
Open access
ECEduardo J Contijoch
Eduardo J Contijoch
GBGraham Britton
Graham Britton
CYChao Yang
Chao Yang
IMIlaria Mogno
Ilaria Mogno
ZLZhihua Li
Zhihua Li
JFJeremiah J Faith
Jeremiah J Faith
To identify factors that regulate gut microbiota density and the impact of varied microbiota density on health, we assayed this fundamental ecosystem property in fecal samples across mammals, human disease, and therapeutic interventions. Physiologic features of the host (carrying capacity) and the fitness of the gut microbiota shape microbiota density. Therapeutic manipulation of microbiota density in mice altered host metabolic and immune homeostasis. In humans, gut microbiota density was reduced in Crohn’s disease, ulcerative colitis, and ileal pouch-anal anastomosis. The gut microbiota in recurrent Clostridium difficile infection had lower density and reduced fitness that were restored by fecal microbiota transplantation. Understanding the interplay between microbiota and disease in terms of microbiota density, host carrying capacity, and microbiota fitness provide new insights into microbiome structure and microbiome targeted therapeutics.